What are the legal requirements for prescribing testosterone (a Schedule III controlled substance) without an in‑person examination, and how long can a clinician go without seeing the patient before a refill?

Legal Requirements for Prescribing Testosterone Without In-Person Examination

Testosterone is a Schedule III controlled substance 1, and federal law requires an in-person medical evaluation before prescribing any controlled substance—you cannot legally prescribe testosterone without first seeing the patient in person. This is a DEA requirement, not just a clinical guideline.

Federal Controlled Substance Requirements

The DEA mandates that prescribers establish a valid doctor-patient relationship before prescribing Schedule III controlled substances like testosterone 1. This requires:

• An in-person physical examination (with limited telemedicine exceptions that vary by state and were temporarily expanded during COVID-19)
• Documentation of a legitimate medical purpose
• Proper medical evaluation and diagnosis

Clinical Follow-Up Intervals

While the law requires an initial in-person visit, the clinical guidelines provide specific monitoring intervals once treatment is established:

Initial Monitoring Phase

• Measure follow-up testosterone levels after an appropriate interval to ensure target levels are achieved 2
• Assess prostate cancer risk at 3-12 months after starting therapy in appropriate patients 3

Ongoing Monitoring

• Testosterone levels should be measured every 6-12 months while on therapy 2
• This represents the maximum interval between clinical assessments

Important Caveats

State laws may be more restrictive than federal requirements. Many states have specific regulations about:

• How frequently controlled substances can be refilled without an office visit
• Telemedicine prescribing limitations for Schedule III substances
• Maximum prescription duration (commonly 90 days for Schedule III)

The clinical guidelines do not address the legal question directly 3, 2—they focus on medical monitoring intervals, not legal prescribing requirements. The 6-12 month monitoring interval 2 is a clinical recommendation for laboratory follow-up, not a legal authorization to prescribe without patient contact.

Practical Algorithm

1. Initial prescription: In-person visit required by federal law
2. Refills within first year: Follow state-specific controlled substance laws (typically require visits every 3-6 months)
3. Established patients: At minimum, see patient every 6-12 months for clinical monitoring 2, but legal requirements for controlled substance prescribing may mandate more frequent visits
4. Check your state medical board and DEA regulations for specific requirements in your jurisdiction

Bottom line: You must see the patient in person initially, and state law will dictate the maximum interval for refills—typically requiring visits more frequently than the 6-12 month clinical monitoring interval.